Pfizer Limited's stock jumped 8% to ₹5,442 after parent Pfizer won a three-year US tariff exemption by agreeing to cut drug prices and boost local investments. Despite this rally, the stock has delivered a negative 11% return in the past year, reflecting weak longer-term performance.